Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth
EquityIndex FundsVery High Risk
Direct
NAV (26-Mar-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹152 Cr
Expense Ratio
0.50%
ISIN
INF754K01LV5
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
26 Oct 2020
About this fund
As of 26-Mar-25, it has a Net Asset Value (NAV) of ₹19.55, Assets Under Management (AUM) of 151.99 Crores, and an expense ratio of 0.5%.
- Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth has given a CAGR return of 16.40% since inception.
- The fund's asset allocation comprises around 100.13% in equities, 0.00% in debts, and -0.13% in cash & cash equivalents.
- You can start investing in Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth with a SIP of ₹100 or a Lumpsum investment of ₹100.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+13.49%
— (Cat Avg.)
3 Years
+15.94%
— (Cat Avg.)
Since Inception
+16.40%
— (Cat Avg.)
Portfolio Summaryas of 28th February 2025
| Equity | ₹152.19 Cr | 100.13% |
| Others | ₹-0.2 Cr | -0.13% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type  | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹18.11 Cr | 11.92% |
| Eli Lilly and Co | Equity | ₹9.64 Cr | 6.34% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹9.01 Cr | 5.93% |
| Cipla Ltd | Equity | ₹8.75 Cr | 5.76% |
| Divi's Laboratories Ltd | Equity | ₹7.76 Cr | 5.10% |
| Dr Reddy's Laboratories Ltd | Equity | ₹7.73 Cr | 5.08% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹7.22 Cr | 4.75% |
| Johnson & Johnson | Equity | ₹5.16 Cr | 3.39% |
| Lupin Ltd | Equity | ₹5.15 Cr | 3.39% |
| AbbVie Inc | Equity | ₹4.8 Cr | 3.16% |
| Torrent Pharmaceuticals Ltd | Equity | ₹3.88 Cr | 2.56% |
| Novo Nordisk AS ADR | Equity | ₹3.79 Cr | 2.49% |
| Net Receivables/(Payables) | Cash - Collateral | ₹-3.6 Cr | 2.37% |
| Fortis Healthcare Ltd | Equity | ₹3.56 Cr | 2.34% |
| Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹3.41 Cr | 2.24% |
| Aurobindo Pharma Ltd | Equity | ₹3.28 Cr | 2.16% |
| Abbott Laboratories | Equity | ₹3.11 Cr | 2.05% |
| Mankind Pharma Ltd | Equity | ₹3.07 Cr | 2.02% |
| Merck & Co Inc | Equity | ₹3.03 Cr | 1.99% |
| Novartis AG ADR | Equity | ₹2.79 Cr | 1.84% |
| Intuitive Surgical Inc | Equity | ₹2.64 Cr | 1.74% |
| Thermo Fisher Scientific Inc | Equity | ₹2.63 Cr | 1.73% |
| Zydus Lifesciences Ltd | Equity | ₹2.61 Cr | 1.72% |
| Alkem Laboratories Ltd | Equity | ₹2.3 Cr | 1.52% |
| Ipca Laboratories Ltd | Equity | ₹2.24 Cr | 1.47% |
| Laurus Labs Ltd | Equity | ₹2.19 Cr | 1.44% |
| Amgen Inc | Equity | ₹2.15 Cr | 1.42% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹2.14 Cr | 1.41% |
| Gilead Sciences Inc | Equity | ₹1.85 Cr | 1.22% |
| Danaher Corp | Equity | ₹1.75 Cr | 1.15% |
| Stryker Corp | Equity | ₹1.72 Cr | 1.13% |
| Vertex Pharmaceuticals Inc | Equity | ₹1.61 Cr | 1.06% |
| Medtronic PLC | Equity | ₹1.53 Cr | 1.01% |
| Biocon Ltd | Equity | ₹1.5 Cr | 0.99% |
| Suven Pharmaceuticals Ltd | Equity | ₹1.47 Cr | 0.96% |
| Syngene International Ltd | Equity | ₹1.4 Cr | 0.92% |
| Gland Pharma Ltd | Equity | ₹1.36 Cr | 0.90% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹1.36 Cr | 0.90% |
| Piramal Pharma Ltd | Equity | ₹1.34 Cr | 0.88% |
| Ajanta Pharma Ltd | Equity | ₹1.29 Cr | 0.85% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.24 Cr | 0.82% |
| Global Health Ltd | Equity | ₹1.1 Cr | 0.72% |
| Regeneron Pharmaceuticals Inc | Equity | ₹0.98 Cr | 0.64% |
| Becton Dickinson & Co | Equity | ₹0.85 Cr | 0.56% |
| Agilent Technologies Inc | Equity | ₹0.48 Cr | 0.31% |
| IQVIA Holdings Inc | Equity | ₹0.44 Cr | 0.29% |
| Illumina Inc | Equity | ₹0.18 Cr | 0.12% |
| Accrued Interest | Cash - Collateral | ₹0 Cr | 0.00% |
Allocation By Market Cap (Equity)
Large Cap Stocks
32.14%
Mid Cap Stocks
28.55%
Small Cap Stocks
5.80%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹152.19 Cr | 100.13% |
Risk & Performance Ratios
Standard Deviation
This fund
13.25%
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
0.76
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Fund Managers
Bhavesh Jain
Since October 2021
Amit Vora
Since February 2021
Additional Scheme Detailsas of 28th February 2025
ISIN INF754K01LV5 | Expense Ratio 0.50% | Exit Load No Charges | Fund Size ₹152 Cr | Age 4 years 5 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark MSCI Ind Dom & Wld HealthC 45 NR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Index Funds Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y  |
|---|---|---|---|---|
| ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹562.26 Cr | 8.4% |
| ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹562.26 Cr | 7.7% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹430.96 Cr | -7.1% |
| SBI Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹657.77 Cr | 7.9% |
| DSP Nifty 50 Equal Weight Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹1945.75 Cr | 5.7% |
| SBI Nifty Smallcap 250 Index Fund Direct Growth Very High Risk | 0.5% | 0.0% | ₹1086.14 Cr | 5.7% |
| SBI Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.5% | 0.0% | ₹657.77 Cr | 8.5% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹430.96 Cr | -6.5% |
| DSP Nifty 50 Equal Weight Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1945.75 Cr | 6.3% |
| SBI Nifty Smallcap 250 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹1086.14 Cr | 5.1% |
About the AMC
Edelweiss Mutual Fund
Total AUM
₹1,62,815 Cr
Address
J.P.Morgan Tower, Mumbai, 400 098
Other Funds by Edelweiss Mutual Fund
Risk Level
Your principal amount will be at Very High Risk
Take control of your wealth
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth?
What are the returns of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth?
What is the portfolio composition of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth?
Who manages the Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth?
- Bhavesh Jain
- Amit Vora
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth
EquityIndex FundsVery High Risk
Direct
NAV (26-Mar-25)
Returns (Since Inception)
Fund Overview
Fund Size
₹152 Cr
Expense Ratio
0.50%
ISIN
INF754K01LV5
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
26 Oct 2020
Risk Level
Your principal amount will be at Very High Risk
About this fund
As of 26-Mar-25, it has a Net Asset Value (NAV) of ₹19.55, Assets Under Management (AUM) of 151.99 Crores, and an expense ratio of 0.5%.
- Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth has given a CAGR return of 16.40% since inception.
- The fund's asset allocation comprises around 100.13% in equities, 0.00% in debts, and -0.13% in cash & cash equivalents.
- You can start investing in Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth with a SIP of ₹100 or a Lumpsum investment of ₹100.
Performance against Category Average
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+13.49%
— (Cat Avg.)
3 Years
+15.94%
— (Cat Avg.)
Since Inception
+16.40%
— (Cat Avg.)
Portfolio Summaryas of 28th February 2025
| Equity | ₹152.19 Cr | 100.13% |
| Others | ₹-0.2 Cr | -0.13% |
Top Holdings
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹18.11 Cr | 11.92% |
| Eli Lilly and Co | Equity | ₹9.64 Cr | 6.34% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹9.01 Cr | 5.93% |
| Cipla Ltd | Equity | ₹8.75 Cr | 5.76% |
| Divi's Laboratories Ltd | Equity | ₹7.76 Cr | 5.10% |
| Dr Reddy's Laboratories Ltd | Equity | ₹7.73 Cr | 5.08% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹7.22 Cr | 4.75% |
| Johnson & Johnson | Equity | ₹5.16 Cr | 3.39% |
| Lupin Ltd | Equity | ₹5.15 Cr | 3.39% |
| AbbVie Inc | Equity | ₹4.8 Cr | 3.16% |
| Torrent Pharmaceuticals Ltd | Equity | ₹3.88 Cr | 2.56% |
| Novo Nordisk AS ADR | Equity | ₹3.79 Cr | 2.49% |
| Net Receivables/(Payables) | Cash - Collateral | ₹-3.6 Cr | 2.37% |
| Fortis Healthcare Ltd | Equity | ₹3.56 Cr | 2.34% |
| Clearing Corporation Of India Ltd. | Cash - Repurchase Agreement | ₹3.41 Cr | 2.24% |
| Aurobindo Pharma Ltd | Equity | ₹3.28 Cr | 2.16% |
| Abbott Laboratories | Equity | ₹3.11 Cr | 2.05% |
| Mankind Pharma Ltd | Equity | ₹3.07 Cr | 2.02% |
| Merck & Co Inc | Equity | ₹3.03 Cr | 1.99% |
| Novartis AG ADR | Equity | ₹2.79 Cr | 1.84% |
| Intuitive Surgical Inc | Equity | ₹2.64 Cr | 1.74% |
| Thermo Fisher Scientific Inc | Equity | ₹2.63 Cr | 1.73% |
| Zydus Lifesciences Ltd | Equity | ₹2.61 Cr | 1.72% |
| Alkem Laboratories Ltd | Equity | ₹2.3 Cr | 1.52% |
| Ipca Laboratories Ltd | Equity | ₹2.24 Cr | 1.47% |
| Laurus Labs Ltd | Equity | ₹2.19 Cr | 1.44% |
| Amgen Inc | Equity | ₹2.15 Cr | 1.42% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹2.14 Cr | 1.41% |
| Gilead Sciences Inc | Equity | ₹1.85 Cr | 1.22% |
| Danaher Corp | Equity | ₹1.75 Cr | 1.15% |
| Stryker Corp | Equity | ₹1.72 Cr | 1.13% |
| Vertex Pharmaceuticals Inc | Equity | ₹1.61 Cr | 1.06% |
| Medtronic PLC | Equity | ₹1.53 Cr | 1.01% |
| Biocon Ltd | Equity | ₹1.5 Cr | 0.99% |
| Suven Pharmaceuticals Ltd | Equity | ₹1.47 Cr | 0.96% |
| Syngene International Ltd | Equity | ₹1.4 Cr | 0.92% |
| Gland Pharma Ltd | Equity | ₹1.36 Cr | 0.90% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹1.36 Cr | 0.90% |
| Piramal Pharma Ltd | Equity | ₹1.34 Cr | 0.88% |
| Ajanta Pharma Ltd | Equity | ₹1.29 Cr | 0.85% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹1.24 Cr | 0.82% |
| Global Health Ltd | Equity | ₹1.1 Cr | 0.72% |
| Regeneron Pharmaceuticals Inc | Equity | ₹0.98 Cr | 0.64% |
| Becton Dickinson & Co | Equity | ₹0.85 Cr | 0.56% |
| Agilent Technologies Inc | Equity | ₹0.48 Cr | 0.31% |
| IQVIA Holdings Inc | Equity | ₹0.44 Cr | 0.29% |
| Illumina Inc | Equity | ₹0.18 Cr | 0.12% |
| Accrued Interest | Cash - Collateral | ₹0 Cr | 0.00% |
Allocation By Market Cap (Equity)
Large Cap Stocks
32.14%
Mid Cap Stocks
28.55%
Small Cap Stocks
5.80%
Other Allocation
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹152.19 Cr | 100.13% |
Risk & Performance Ratios
Standard Deviation
This fund
13.25%
Cat. avg.
--
Lower the better
Sharpe Ratio
This fund
0.76
Cat. avg.
--
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
--
Higher the better
Fund Managers
Bhavesh Jain
Since October 2021
Amit Vora
Since February 2021
Additional Scheme Detailsas of 28th February 2025
ISIN INF754K01LV5 | Expense Ratio 0.50% | Exit Load No Charges | Fund Size ₹152 Cr | Age 4 years 5 months | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark MSCI Ind Dom & Wld HealthC 45 NR INR |
Investment Objective
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Tax Treatment
Capital Gains Taxation:
Dividend Taxation:
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Similar Index Funds Funds
| Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
|---|---|---|---|---|
| ICICI Prudential Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.3% | 0.0% | ₹562.26 Cr | 8.4% |
| ICICI Prudential Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹562.26 Cr | 7.7% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Regular Growth Very High Risk | 1.0% | 0.0% | ₹430.96 Cr | -7.1% |
| SBI Nifty Midcap 150 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹657.77 Cr | 7.9% |
| DSP Nifty 50 Equal Weight Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹1945.75 Cr | 5.7% |
| SBI Nifty Smallcap 250 Index Fund Direct Growth Very High Risk | 0.5% | 0.0% | ₹1086.14 Cr | 5.7% |
| SBI Nifty Midcap 150 Index Fund Direct Growth Very High Risk | 0.5% | 0.0% | ₹657.77 Cr | 8.5% |
| ICICI Prudential Nifty 200 Momentum 30 Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹430.96 Cr | -6.5% |
| DSP Nifty 50 Equal Weight Index Fund Direct Growth Very High Risk | 0.4% | 0.0% | ₹1945.75 Cr | 6.3% |
| SBI Nifty Smallcap 250 Index Fund Regular Growth Very High Risk | 0.9% | 0.0% | ₹1086.14 Cr | 5.1% |
About the AMC
Edelweiss Mutual Fund
Total AUM
₹1,62,815 Cr
Address
J.P.Morgan Tower, Mumbai, 400 098
Other Funds by Edelweiss Mutual Fund
Related Articles
Still got questions?
We're here to help.
What is the current NAV of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth?
What are the returns of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth?
What is the portfolio composition of Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth?
Who manages the Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth?
- Bhavesh Jain
- Amit Vora
Track & Analyse all your investments in one place
Compare your portfolio's performance with benchmarks
Identify potential risks in your portfolio and learn to fix them
Track all your family's investments in one place
Trending Mutual Funds Searches
Popular Equity Funds
Popular Debt Funds
Track all you investments in one place
Download Wealth Monitor App
Dezerv Investments Private Limited is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.
Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.
Get your portfolio reviewed by experts
